Enhancement of non-specific antiviral immunity induced by mucosal administration of immunoadijivant in infant animal

1.分别用仙台病毒、轮状病毒和汉坦病毒建立小鼠呼吸道感染、肠道感染和全身感染的动物模型。选择MDP-Lys(L18)作为免疫佐剂，考察其经口、鼻腔、直肠和皮下给药后对感染的增强保护作用。MDP-Lys(L18)经鼻腔、口腔甚至直肠途径给药，可显著降低致死性仙台病毒感染。MDP-Lys(L18)皮下、口服和直肠给药可显著减轻轮状病毒腹泻小鼠的腹泻症状。只有皮下注射MDP-Lys(L18)才能显著降低致死性汉坦病毒感染，提示免疫佐剂对普通黏膜免疫系统增强宿主免疫有一定作用。关于宿主免疫增强的定量估计的进一步研究。此外，免疫佐剂与粘膜给药相结合，增强对疫苗抗原的特异性免疫作用也值得研究。

1. Animal models for studying respiratory infection, enteric infection and systemic infections were established by using mice and Sendai virus, rotavirus and hantavirus, respectively.2. MDP-Lys (L18) was selected as a immunoadjuvant and examined its effect on the enhancement of protection from infection after its administration by oral, intranasal, intrarectal and subcutaneous routes.3. Fatal Sendai virus infection was significantly reduced by administration of MDP-Lys (L18) through intranasal, ora and even intra rectal route.4. Rota virus diarrhea was significantly reduced by administration of MDP-Lys (L18) through subcutaneous, oral and intrarectal route.5. Fatal hantavirus infection was significantly reduced only by the administration of MDP-Lys (L18) through subcutaneous route.These results suggested the effect of immunoadjuvant on the augmentation of host immunity by common mucosa immune system. Further studies concerning to the quantitative estimation of the augmentation of host immunity. In addition, enhancement of specific immunity against vaccine antigen by the combination of the immunoadjuvant and mucosal administration should be studied.